TY - JOUR
T1 - Prognostic Value of MicroRNAs in Stage II Colorectal Cancer Patients
T2 - A Systematic Review and Meta-Analysis
AU - Sabarimurugan, Shanthi
AU - Madhav, Madurantakam Royam
AU - Kumarasamy, Chellan
AU - Gupta, Ajay
AU - Baxi, Siddharta
AU - Krishnan, Sunil
AU - Jayaraj, Rama
PY - 2020/2
Y1 - 2020/2
N2 - Background: We performed a systematic review and meta-analysis to identify and underline multiple microRNAs (miRNAs) as biomarkers of disease prognosis in stage II colorectal cancer (CRC) patients. Methods and analysis: This systematic review and meta-analysis study was conducted according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. The required articles were collected from online bibliographic databases from January 2011 to November 2019 with multiple permutation keywords. Quantitative data synthesis was based on a meta-analysis with pooled data to observe and analyse the outcome measures and effect estimates by using the random effect model. The subgroup analysis was performed from demographic characteristics and the available data. Results: Eighteen articles were included in this study, 16 of which were incorporated for meta-analysis to examine the stage II CRC prognosis with up- and downregulated miRNA expressions. The pooled hazard ratio (HR) for death in stage II CRC patients was 1.90 (95% confidence interval 1.63–2.211), with a significant p value. A subgroup analysis based on up- or downregulated miRNA expression individually and any deregulated miRNA was also associated with a worse prognosis. The subgroup analysis included parameters such as age, gender, stage II and III combined patients’ survival and the repetitive miRNAs (miR21, miR215, miR143-5p, miR106a and miR145) individually. Conclusion: MicroRNAs play a significant role in determining prognosis in stage II CRC patients, with upregulation of miR21, miR215, miR143-5p and miR106a, in particular, portending a worse prognosis. These miRNAs could be considered for further evaluation as biomarkers of prognosis and to guide the decision to administer adjuvant chemotherapy.
AB - Background: We performed a systematic review and meta-analysis to identify and underline multiple microRNAs (miRNAs) as biomarkers of disease prognosis in stage II colorectal cancer (CRC) patients. Methods and analysis: This systematic review and meta-analysis study was conducted according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. The required articles were collected from online bibliographic databases from January 2011 to November 2019 with multiple permutation keywords. Quantitative data synthesis was based on a meta-analysis with pooled data to observe and analyse the outcome measures and effect estimates by using the random effect model. The subgroup analysis was performed from demographic characteristics and the available data. Results: Eighteen articles were included in this study, 16 of which were incorporated for meta-analysis to examine the stage II CRC prognosis with up- and downregulated miRNA expressions. The pooled hazard ratio (HR) for death in stage II CRC patients was 1.90 (95% confidence interval 1.63–2.211), with a significant p value. A subgroup analysis based on up- or downregulated miRNA expression individually and any deregulated miRNA was also associated with a worse prognosis. The subgroup analysis included parameters such as age, gender, stage II and III combined patients’ survival and the repetitive miRNAs (miR21, miR215, miR143-5p, miR106a and miR145) individually. Conclusion: MicroRNAs play a significant role in determining prognosis in stage II CRC patients, with upregulation of miR21, miR215, miR143-5p and miR106a, in particular, portending a worse prognosis. These miRNAs could be considered for further evaluation as biomarkers of prognosis and to guide the decision to administer adjuvant chemotherapy.
UR - http://www.scopus.com/inward/record.url?scp=85079358052&partnerID=8YFLogxK
U2 - 10.1007/s40291-019-00440-y
DO - 10.1007/s40291-019-00440-y
M3 - Review article
C2 - 32020560
AN - SCOPUS:85079358052
VL - 24
SP - 15
EP - 30
JO - Molecular Diagnosis and Therapy
JF - Molecular Diagnosis and Therapy
SN - 1084-8592
IS - 1
ER -